|
1
|
Chou AJ and Gorlick R: Chemotherapy
resistance in osteosarcoma: Current challenges and future
directions. Expert Rev Anticancer There. 6:1075–1085. 2006.
View Article : Google Scholar
|
|
2
|
Longhi A, Errani C, De Paolis M, Mercuri M
and Bacci G: Primary bone osteosarcoma in the pediatric age: State
of the art. Cancer Treat Rev. 32:423–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chou AJ, Merola PR, Wexler LH, Gorlick RG,
Vyas YM, Healey JH, LaQuaglia MP, Huvos AG and Meyers PA: Treatment
of osteosarcoma at first recurrence after contemporary therapy: The
memorial Sloan-Kettering cancer center experience. Cancer.
104:2214–2221. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guo W, Xu W, Huvos AG, Healey JH and Feng
C: Comparative frequency of bone sarcomas among different racial
groups. Chin Med J (Engl). 112:1101–1104. 1999.PubMed/NCBI
|
|
5
|
Marina N, Gebhardt M, Teot L and Gorlick
R: Biology and therapeutic advances for pediatric osteosarcoma.
Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ferguson WS and Goorin AM: Current
treatment of osteosarcoma. Cancer Invest. 19:292–315. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Luetke A, Meyers PA, Lewis A and Juergens
H: Osteosarcoma treatment-where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chou AJ, Geller DS and Gorlick R: Therapy
for osteosarcoma: Where do we go from here? Paediatr Drugs.
10:315–327. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mann J: Natural products in cancer
chemotherapy: Past, present and future. Nat Rev Cancer. 2:143–148.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Middleton EJ, Kandaswami C and Theoharides
TC: The effects of plant flavonoids on mammalian cells:
Implications for inflammation, heart disease, and cancer. Pharmacol
Rev. 52:673–751. 2000.PubMed/NCBI
|
|
11
|
Galati G, Teng S, Moridani MY, Chan TS and
O'Brien PJ: Cancer chemoprevention and apoptosis mechanisms induced
by dietary polyphenolics. Drug Metabol Drug Interact. 17:311–349.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang CS, Landau JM, Huang MT and Newmark
HL: Inhibition of carcinogenesis by dietary polyphenolic compounds.
Annu Rev Nutr. 21:381–406. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Birt DF, Hendrich S and Wang W: Dietary
agents in cancer prevention Flavonoids and isoflavonoids. Pharmacol
Ther. 90:157–177. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Egan D, O'kennedy R, Moran E, Cox D,
Prosser E and Thornes RD: The pharmacology, metabolism, analysis,
and applications of coumarin and coumarin-related compounds. Drug
Metab Rev. 22:503–529. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Francisco CS, Rodrigues LR, Cerqueira NM,
Oliveira-Campos AM and Rodrigues LM: Synthesis of novel
benzofurocoumarin analogues and their anti-proliferative effect on
human cancer cell lines. Eur J Med Chem. 47:370–376. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Velasco-Velázquez MA, Agramonte-Hevia J,
Barrera D, Jiménez-Orozco A, Garcı́a-Mondragón MJ, Mendoza-Patiño
N, Landa A and Mandoki J: 4-Hydroxycoumarin disorganizes the actin
cytoskeleton in B16-F10 melanoma cells but not in B82 fibroblasts,
decreasing their adhesion to extracellular matrix proteins and
motility. Cancer Lett. 198:179–186. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fu-FS, Yin J, Xu K and Huang J: Growth
factors and corneal epithelial wound healing. Brain Res Bull.
81:229–235. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Krambeck AE, Thompson RH, Dong H, Lohse
CM, Park ES, Kuntz SM, Leibovich BC, Blute ML, Cheville JC and Kwon
ED: B7-H4 expression in renal cell carcinoma and tumor vasculature:
Associations with cancer progression and survival. Proc Natl Acad
Sci USA. 103:10391–10396. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bellacosa A, Kumar CC, Di Cristofano A and
Testa JR: Activation of AKT kinases in cancer: Implications for
therapeutic targeting. Adv Cancer Res. 94:29–86. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Panno ML, Giordano F, Mastroianni F, Palma
MG, Bartella V, Carpino A, Aquila S and Andò S: Breast cancer cell
survival signal is affected by bergapten combined with an
ultraviolet irradiation. FEBS Lett. 584:2321–2326. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Finlan LE, Kernohan NM, Thomson G, Beattie
PE, Hupp TR and Ibbotson SH: Differential effects of
5-aminolaevulinic acid photodynamic therapy and
psoralen+ultraviolet A therapy on p53 phosphorylation in normal
human skin in vivo. Br J Dermatol. 153:1001–10010. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kleiner HE, Reed MJ and DiGiovanni J:
Naturally occurring coumarins inhibit human cytochromes P450 and
block benzo[a]pyrene and 7, 12-dimethylbenz[a]anthracene DNA adduct
formation in MCF-7 cells. Chem Res Toxicol. 16:415–422. 2003.
View Article : Google Scholar : PubMed/NCBI
|
